XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.18

-5.1%

Dec 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Olu Emuleomo who started this subject	8/7/2002 11:00:15 AM
From: aknahow	of 17367

Stolen from the XOMA Group at Yahoo. Was unable to copy directly from AH&H site. Xoma (XOMA, $4.35, $305MM market cap, $9 price target) * Reviewed positive results from chronic use study with Xanelim for moderate-to-severe psoriasis. * We continue to expect Genentech to file for U.S. approval of Xanelim in Q4 of 2002 following positive results from the third Phase III trial (due in Q4). Per Genentech's May 2002 meeting with the FDA, the companies DO NOT need to meet the ICH guidelines for the Genentech-manufactured material. * Genentech/Xoma will submit a CTD for approval (common technical document, more extensive than a BLA, will enable worldwide filings with one document). Xoma expects a European partner for Xanelim to be announced "soon." CTD document plus the partner could lead to approval in Europe prior to our current 2005 expectation. * Xoma expects to enter the clinic with products partnered with Millennium in early 2003.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next